Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Delayed Quote. Delayed  - 07/22 05:39:37 pm
76.6 EUR   +0.50%
07/22 PROMIS NEUROSCI : Announces Appointment of Dr. Johanne Kaplan as Chi..
07/21 SANOFI : Information concerning the total number of voting rights an..
07/21 JUNIPER PHARMAC : Appoints Alicia Secor President and Chief Executiv..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

SANOFI : Combined General Shareholder Meeting of May 4, 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:35pm CEST
PRESS RELEASE Combined General Shareholder Meeting of May 4, 2012

? Shareholder approval of the corporate and consolidated financial statements for 2011

? Dividend of ?2.65 per share payable as of May 15, 2012

? Nomination of a new director

? Partial renewal of the Board of Directors

Paris, France - May 4, 2012 - Sanofi (EURONEXT : SAN et NYSE : SNY) announced its Combined General Shareholder Meeting was held today at the Palais des Congrès in Paris. All resolutions were adopted by its shareholders.

During the meeting, shareholders approved, among other resolutions, the corporate and consolidated financial statements for the year 2011. At the General Meeting, shareholders decided the distribution of a dividend in the amount of ?2.65 per share that will be detached on Euronext Paris on May 10, 2012 with payment as of May 15, 2012.
The General Meeting also approved the appointment of Mr. Laurent Attal as a director for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year
2015. Finally, Mr. Uwe Bicker, Mr. Jean-René Fourtou, Ms. Claudie Haigneré, Ms. Carole Piwnica and Mr. Klaus Pohle have each been reappointed for a term of four years.
After the Shareholder Meeting, the Board of Directors is comprised as follows:

? Serge Weinberg, Chairman of the Board of Directors

? Christopher Viehbacher, Chief Executive Officer

? Laurent Attal

? Uwe Bicker

? Robert Castaigne

? Thierry Desmarest

? Lord Douro

? Jean-René Fourtou

? Claudie Haigneré

? Igor Landau

? Suet-Fern Lee

? Christian Mulliez

? Carole Piwnica

? Klaus Pohle

? Gérard Van Kemmel

During the meeting, the shareholders approved the appointment of statutory and deputy auditors. The shareholders additionally ratified the move of the registered headquarters of Sanofi to 54, rue La Boétie, 75008 Paris. During the Board of Directors session following the meeting, Mr. Klaus Pohle was renewed as Chairman of the Audit Committee.

1/2

The voting results will be available on the company's website (www.sanofi.com) in the coming days.
The audiocast of the Combined General Shareholder Meeting is available on the Company's website (www.sanofi.com).

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:

Media Relations Investor Relations

Jean-Marc Podvin Sébastien Martel

+ (33) 1 53 77 46 46 + (33) 1 53 77 45 45 mr@sanofi.com ir@sanofi.com

2/2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07/22 PROMIS NEUROSCIENCES : Announces Appointment of Dr. Johanne Kaplan as Chief Deve..
07/21 SANOFI : Information concerning the total number of voting rights and shares, pr..
07/21 JUNIPER PHARMACEUTICALS : Appoints Alicia Secor President and Chief Executive Of..
07/20 JUNIPER PHARMACEUTICALS INC : Change in Directors or Principal Officers, Regulat..
07/15 SANOFI : Pasteur signs research agreement for Zika vaccine
07/14 MEDIVATION : Enters into Confidentiality Agreements, Including with Sanofi
07/14 SANOFI : Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Pati..
07/14 SANOFI : Patent Issued for Neutralizing Immunogen (NimIV) of Rhinovirus and Its ..
07/14 SANOFI : Army researchers team with Sanofi Pasteur to co-develop a Zika virus va..
07/14 FINDINGS FROM SANOFI PROVIDE NEW INS : Integration into Clinical...
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 MannKind - Afrezza Sales Pacing Below My Bearish Line - Reality May Sting
07/22 Re-Evaluation Of LDL Cholesterol-Level Impacts Could Benefit Amarin's Vascepa
07/22 WALL STREET BREAKFAST : Markets Get First Glimpse Of Post-Brexit Data
07/22 More Zika worries
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
Advertisement
Financials (€)
Sales 2016 37 117 M
EBIT 2016 9 360 M
Net income 2016 5 093 M
Debt 2016 5 594 M
Yield 2016 3,92%
P/E ratio 2016 18,60
P/E ratio 2017 16,10
EV / Sales 2016 2,81x
EV / Sales 2017 2,75x
Capitalization 98 592 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,0 €
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-3.03%108 205
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.53%219 526
ROCHE HOLDING LTD.-9.55%218 832
MERCK & CO., INC.11.36%162 815
More Results